AbbVie is buying Botox maker Allergan for $63 billion – a 45% premium. It’s a great deal for the seller’s shareholders, but not much more than an overpriced superficial filler for the buyer, rob_cyran explains.
AbbVie is buying Allergan, maker of Botox, for $63 billion – a 45% premium. It’s a great deal for the seller’s shareholders, but not much more than an overpriced superficial filler for the buyer. Robert Cyran explains the wrinkles in the merger.
Press CTRL+C (Windows), CMD+C (Mac), or long-press the URL below on your mobile device to copy the codeRead more: ReutersBreakingviews
AbbVie looks beyond Humira with $63 billion deal for Botox-maker AllerganDrugmaker AbbVie Inc said on Tuesday it would buy Botox-maker Allergan Plc for a... Mental price. Allergan are in a terrible state. Drugs, solving all of America's problems.
Allergan spikes 30% after AbbVie agrees to buy the Botox-maker for $63 billionAbbVie expects the acquisition to generate at least $2 billion in pre-tax synergies and cost reductions within three years.
AbbVie to acquire Botox maker Allergan with $63-billion bidAbbVie said it will pay $120.30 in cash and a portion of AbbVie stock for each Allergan share. No one has $63 billion dollars in Cash. And I am out. ✌️ These greedy billionaires throwing it around like confetti and the veterans that fight for the country's freedom come home and get almost zero help ... Money isn't the root of all evil .... The LOVE of money is . 63 billion is more than most Countries own . FFS.
Botox Maker Allergan Is Sold to AbbVie in $63 Billion DealThe transaction would give AbbVie a potent source of popular treatments as it faces the loss of patent protection for its best-selling drug, Humira. $63,000,000,000... Boy, there sure is a lot of $$$ in the vanity market. MillerKCaitlin1 It's not worth more than 62999000000 999000 + 99 cents are overpaying 🤣😅😂💯 these drug makers have so many billions, at the cost of ordinary citizens, trying 2 pay 4 their medications
Aging AbbVie turns to ugly $63 bln Botox remedyThe drug maker’s Humira accounts for more than half its sales but may soon face competition. Buying Botox maker Allergan at a 45% premium looks like an excessively expensive and temporary face-lift. AbbVie’s money and time could be better spent on more invigorating targets.
https://www.instyle.comInStyle is the leading site for celebrity style. See expert fashion advice, star hairstyles, beauty tips, how-to videos and real-time red carpet coverage.